How do I install the Es Cgm Vs None T2d Insu Su High Risk skill?

Run npx skillmds@latest add dromlakhani/es-cgm-vs-none-t2d-insu-su-high-risk in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Es Cgm Vs None T2d Insu Su High Risk safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: makes network calls. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Es Cgm Vs None T2d Insu Su High Risk?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Es Cgm Vs None T2d Insu Su High Risk free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Es Cgm Vs None T2d Insu Su High Risk?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Es Cgm Vs None T2d Insu Su High Risk by dromlakhani

Name: Es Cgm Vs None T2d Insu Su High Risk
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Es Cgm Vs None T2d Insu Su High Risk

This skill suggests using real-time continuous glucose monitoring (CGM) rather than no CGM for outpatients with type 2 diabetes (T2D) who take insulin and/or sulfonylureas and are at high risk for hypoglycemia. It is triggered by clinician questions such as "Should I use CGM for this T2D patient on insulin or sulfonylureas with high hypoglycemia risk?" or "Is CGM indicated for this patient?"

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

CGM vs No CGM for T2D on Insulin/SU at High Risk

STEP 1 — Gather Information

Collect patient demographics, confirm type 2 diabetes outpatient status, list current medications (focus on insulin and/or sulfonylureas), and document hypoglycemia history (severe episodes requiring assistance, impaired awareness of hypoglycemia, renal/hepatic dysfunction, age-related risk).

STEP 2 — Rule In / Rule Out

Determine if the patient is an outpatient with T2D prescribed insulin and/or a sulfonylurea. If yes, proceed to assess hypoglycemia risk; if no, CGM is not indicated per this recommendation (stop).

STEP 3 — Classify or Stratify

Assess for high hypoglycemia risk: history of severe hypoglycemia requiring assistance, impaired awareness of hypoglycemia (IAH), or medical conditions predisposing to severe hypoglycemia (renal/hepatic dysfunction, older age). If high risk, proceed; if not high risk, CGM is not suggested per this guideline (though consider other indications).

STEP 4 — Decide

For patients meeting criteria (T2D outpatient on insulin/SU and high hypoglycemia risk), suggest initiating real-time CGM rather than no CGM, combined with periodic point-of-care blood glucose (POC-BG) testing to validate CGM accuracy.

Clinical Guardrails / Mimics / Pitfalls

CGM does not replace SMBG; fingerstick glucose remains necessary for calibration, confirmation of discordant symptoms, and sensor warm-up periods. Ensure patient receives education on device use, troubleshooting, interpreting trend arrows, and responding to alerts. Be mindful of cost, insurance coverage, and patient acceptability; avoid using CGM alone for acute treatment decisions without confirmatory SMBG. Note that inpatient CGM use lacks FDA approval but may be used under enforcement discretion; assess patient ability to handle device alerts and data burden.

Concrete Clinical Example

A 68‑year‑old man with T2D on basal insulin glargine and glimepiride (a sulfonylurea) reports recurrent hypoglycemia unawareness and two severe hypoglycemic events requiring assistance in the past month. He is an outpatient on insulin/SU and at high risk. The skill suggests initiating real‑time CGM with diabetes education and periodic SMBG validation.

Source: Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

---name: es-cgm-vs-none-t2d-insu-su-high-riskdescription: This skill suggests using real-time continuous glucose monitoring (CGM) rather than no CGM for outpatients with type 2 diabetes (T2D) who take insulin and/or sulfonylureas and are at high risk for hypoglycemia. It is triggered by clinician questions such as "Should I use CGM for this T2D patient on insulin or sulfonylureas with high hypoglycemia risk?" or "Is CGM indicated for this patient?"---# CGM vs No CGM for T2D on Insulin/SU at High Risk## STEP 1 — Gather InformationCollect patient demographics, confirm type 2 diabetes outpatient status, list current medications (focus on insulin and/or sulfonylureas), and document hypoglycemia history (severe episodes requiring assistance, impaired awareness of hypoglycemia, renal/hepatic dysfunction, age-related risk).## STEP 2 — Rule In / Rule OutDetermine if the patient is an outpatient with T2D prescribed insulin and/or a sulfonylurea. If yes, proceed to assess hypoglycemia risk; if no, CGM is not indicated per this recommendation (stop).## STEP 3 — Classify or StratifyAssess for high hypoglycemia risk: history of severe hypoglycemia requiring assistance, impaired awareness of hypoglycemia (IAH), or medical conditions predisposing to severe hypoglycemia (renal/hepatic dysfunction, older age). If high risk, proceed; if not high risk, CGM is not suggested per this guideline (though consider other indications).## STEP 4 — DecideFor patients meeting criteria (T2D outpatient on insulin/SU and high hypoglycemia risk), suggest initiating real-time CGM rather than no CGM, combined with periodic point-of-care blood glucose (POC-BG) testing to validate CGM accuracy.## Clinical Guardrails / Mimics / PitfallsCGM does not replace SMBG; fingerstick glucose remains necessary for calibration, confirmation of discordant symptoms, and sensor warm-up periods. Ensure patient receives education on device use, troubleshooting, interpreting trend arrows, and responding to alerts. Be mindful of cost, insurance coverage, and patient acceptability; avoid using CGM alone for acute treatment decisions without confirmatory SMBG. Note that inpatient CGM use lacks FDA approval but may be used under enforcement discretion; assess patient ability to handle device alerts and data burden.## Concrete Clinical ExampleA 68‑year‑old man with T2D on basal insulin glargine and glimepiride (a sulfonylurea) reports recurrent hypoglycemia unawareness and two severe hypoglycemic events requiring assistance in the past month. He is an outpatient on insulin/SU and at high risk. The skill suggests initiating real‑time CGM with diabetes education and periodic SMBG validation.**Source:** Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596

Frequently asked questions